NeurAxis, Inc. NRXS

Full chart Compare
Set alert

Price alert · NRXS

All alert types
6.86 USD +0.28 (+4.26%)

At closeNov 4, 2026, 4:00 PM EST

6.76 -0.10 -1.46%

After hours · Nov 4, 4:00 PM ET

6.51 Day range 6.87
2.21 52-week range 9.33
YTD
+51.10%
1 year
+170.08%
Market cap
86.15M
Revenue (ttm)
2.27M
EPS (ttm)
-0.78
Shares out
6.98M
Forward P/E
-23.30
YTD return
+51.10%
1-year return
+170.08%
Volume
98.25K
Avg volume
129.32K
Open
6.71
Previous close
6.58
Day's range
6.51 – 6.87
52-week range
2.21 – 9.33

2Y +3.97 (+152.11%)

2.5057.50Jan 25Jun 25Nov 25Mar 26Aug 266.58

Key statistics

Enterprise value
24.97M
PEG ratio
0.00
Price / sales
7.17
Price / book
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-5.30%
Free cash flow
-10.40M
Total cash
1.77M
Total debt
5.11M
Return on equity
0.00%
Short % of float
0.18%
50-day average
2.83
200-day average
3.01

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
NRXS Revenue — quarterly 1.93M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
NRXS Net income — quarterly -2.09M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
NRXS EPS — quarterly -0.19
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

NRXS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 20240.00-0.25——
Aug 9, 2024Jun 1, 20240.00-0.42——
May 20, 2024Mar 1, 20240.00-0.32——
Nov 20, 2023Sep 1, 20230.00-1.06——

About NeurAxis, Inc.

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
neuraxis.com

News

Your note

Sign in to keep a note on NRXS — it syncs with the Stock Master app.

Insider holders

NRXS insider holders
InsiderRelationLatest transactionDateShares held
FERGE KRISTIN ADirectorStock Award(Grant)Jun 27, 20241,183
HANNASCH BRIANBeneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Feb 19, 2024757,901
KEYSER JANE ELIZABETHDirectorStock Award(Grant)Jun 27, 202411,580
MASIMO CORP.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityAug 10, 2023531,548
WATKINS BRADLEY MITCHELLDirectorStock Award(Grant)Jun 27, 202411,580

Institution ownership

NRXS institution ownership
Holder% heldSharesValueReported
Bank of Montreal /CAN/2.13%149,017347.21KSep 29, 2024
Vanguard Group Inc0.40%27,98165.19KSep 29, 2024
Stifel Financial Corporation0.37%25,71059.90KSep 29, 2024
Geode Capital Management, LLC0.33%22,70452.90KSep 29, 2024
Royal Bank of Canada0.22%15,10135.19KSep 29, 2024
Parsons Capital Management, Inc.0.19%13,00030.29KSep 29, 2024

Fund ownership

NRXS fund ownership
Holder% heldSharesValueReported
Vanguard Extended Market Index Fund0.25%17,74541.34KSep 29, 2024
Fidelity Extended Market Index Fund0.25%17,75541.37KOct 30, 2024
Vanguard Total Stock Market Index Fund0.15%10,23623.85KSep 29, 2024
Fidelity Series Total Market Index Fund0.06%4,2619.93KOct 30, 2024